Cargando…

Patient-reported QoL in anal cancer survivors 3 and 6 years after treatment—results from the Swedish national ANCA study

PURPOSE: The impact of anal cancer treatment for the patients is best evaluated by the patients themselves. The purpose of this study was to investigate quality of life (QoL) in patients with anal cancer at 3 and 6 years after treatment. METHODS: A Swedish national cross-sectional prospective cohort...

Descripción completa

Detalles Bibliográficos
Autores principales: Axelsson, Anna, Johansson, Mia, Bock, David, Haglind, Eva, de la Croix, Hanna, Nilsson, Per J., Angenete, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942973/
https://www.ncbi.nlm.nih.gov/pubmed/35079906
http://dx.doi.org/10.1007/s00520-021-06769-7
_version_ 1784673418518462464
author Axelsson, Anna
Johansson, Mia
Bock, David
Haglind, Eva
de la Croix, Hanna
Nilsson, Per J.
Angenete, Eva
author_facet Axelsson, Anna
Johansson, Mia
Bock, David
Haglind, Eva
de la Croix, Hanna
Nilsson, Per J.
Angenete, Eva
author_sort Axelsson, Anna
collection PubMed
description PURPOSE: The impact of anal cancer treatment for the patients is best evaluated by the patients themselves. The purpose of this study was to investigate quality of life (QoL) in patients with anal cancer at 3 and 6 years after treatment. METHODS: A Swedish national cross-sectional prospective cohort study with patients diagnosed with anal cancer between 2011 and 2013. Patients were invited to respond to a QoL questionnaire at 3 and 6 years, with focus on bowel, urinary and sexual function, social and mental function, co-morbidity, lifestyle, daily activities, personal characteristics, and perceived QoL. It also contained questions on the severity of the symptoms regarding occurrence, frequency, and duration and the level of “bother” experienced related to functional symptoms. QoL and prevalence of bother with urinary, sexual, bowel dysfunction, and anal pain were described. The prevalence of impaired QoL was compared with a healthy reference population. The association between QoL and experiencing bother was quantified by regression models. RESULTS: From an original cohort of 464 patients with anal cancer, 264 (57%) were alive and contacted at 3 years and 230 (50%) at 6 years. One hundred ninety-five (74%) patients responded to the 3-year and 152 (66%) to the 6-year questionnaire. Sixty percent reported low QoL at both 3 and 6 years. Impaired QoL was more prevalent among patients with major bother due to bowel dysfunction (at 3 years RR 1.42, 95% CI (1.06–1.9) p-value 0.020, at 6 years RR 1.52, 95% CI (1.03–2.24) p-value 0.034) and urinary dysfunction (at 6 years RR 1.44, 95% CI (1.08–1.91) p-value 0.013). There was a tendency to a positive relationship between the number of bodily functions causing bother and risk for impaired QoL. CONCLUSION: Patients treated for anal cancer reported bother regarding several bodily functions as well as poor QoL both at 3 and 6 years without much improvement. Bother was also associated with low QoL indicating that function-related bother should be addressed.
format Online
Article
Text
id pubmed-8942973
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-89429732022-04-07 Patient-reported QoL in anal cancer survivors 3 and 6 years after treatment—results from the Swedish national ANCA study Axelsson, Anna Johansson, Mia Bock, David Haglind, Eva de la Croix, Hanna Nilsson, Per J. Angenete, Eva Support Care Cancer Original Article PURPOSE: The impact of anal cancer treatment for the patients is best evaluated by the patients themselves. The purpose of this study was to investigate quality of life (QoL) in patients with anal cancer at 3 and 6 years after treatment. METHODS: A Swedish national cross-sectional prospective cohort study with patients diagnosed with anal cancer between 2011 and 2013. Patients were invited to respond to a QoL questionnaire at 3 and 6 years, with focus on bowel, urinary and sexual function, social and mental function, co-morbidity, lifestyle, daily activities, personal characteristics, and perceived QoL. It also contained questions on the severity of the symptoms regarding occurrence, frequency, and duration and the level of “bother” experienced related to functional symptoms. QoL and prevalence of bother with urinary, sexual, bowel dysfunction, and anal pain were described. The prevalence of impaired QoL was compared with a healthy reference population. The association between QoL and experiencing bother was quantified by regression models. RESULTS: From an original cohort of 464 patients with anal cancer, 264 (57%) were alive and contacted at 3 years and 230 (50%) at 6 years. One hundred ninety-five (74%) patients responded to the 3-year and 152 (66%) to the 6-year questionnaire. Sixty percent reported low QoL at both 3 and 6 years. Impaired QoL was more prevalent among patients with major bother due to bowel dysfunction (at 3 years RR 1.42, 95% CI (1.06–1.9) p-value 0.020, at 6 years RR 1.52, 95% CI (1.03–2.24) p-value 0.034) and urinary dysfunction (at 6 years RR 1.44, 95% CI (1.08–1.91) p-value 0.013). There was a tendency to a positive relationship between the number of bodily functions causing bother and risk for impaired QoL. CONCLUSION: Patients treated for anal cancer reported bother regarding several bodily functions as well as poor QoL both at 3 and 6 years without much improvement. Bother was also associated with low QoL indicating that function-related bother should be addressed. Springer Berlin Heidelberg 2022-01-26 2022 /pmc/articles/PMC8942973/ /pubmed/35079906 http://dx.doi.org/10.1007/s00520-021-06769-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Axelsson, Anna
Johansson, Mia
Bock, David
Haglind, Eva
de la Croix, Hanna
Nilsson, Per J.
Angenete, Eva
Patient-reported QoL in anal cancer survivors 3 and 6 years after treatment—results from the Swedish national ANCA study
title Patient-reported QoL in anal cancer survivors 3 and 6 years after treatment—results from the Swedish national ANCA study
title_full Patient-reported QoL in anal cancer survivors 3 and 6 years after treatment—results from the Swedish national ANCA study
title_fullStr Patient-reported QoL in anal cancer survivors 3 and 6 years after treatment—results from the Swedish national ANCA study
title_full_unstemmed Patient-reported QoL in anal cancer survivors 3 and 6 years after treatment—results from the Swedish national ANCA study
title_short Patient-reported QoL in anal cancer survivors 3 and 6 years after treatment—results from the Swedish national ANCA study
title_sort patient-reported qol in anal cancer survivors 3 and 6 years after treatment—results from the swedish national anca study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942973/
https://www.ncbi.nlm.nih.gov/pubmed/35079906
http://dx.doi.org/10.1007/s00520-021-06769-7
work_keys_str_mv AT axelssonanna patientreportedqolinanalcancersurvivors3and6yearsaftertreatmentresultsfromtheswedishnationalancastudy
AT johanssonmia patientreportedqolinanalcancersurvivors3and6yearsaftertreatmentresultsfromtheswedishnationalancastudy
AT bockdavid patientreportedqolinanalcancersurvivors3and6yearsaftertreatmentresultsfromtheswedishnationalancastudy
AT haglindeva patientreportedqolinanalcancersurvivors3and6yearsaftertreatmentresultsfromtheswedishnationalancastudy
AT delacroixhanna patientreportedqolinanalcancersurvivors3and6yearsaftertreatmentresultsfromtheswedishnationalancastudy
AT nilssonperj patientreportedqolinanalcancersurvivors3and6yearsaftertreatmentresultsfromtheswedishnationalancastudy
AT angeneteeva patientreportedqolinanalcancersurvivors3and6yearsaftertreatmentresultsfromtheswedishnationalancastudy